» Articles » PMID: 25695162

Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation

Abstract

Constitutively active mutant KRas displays a reduced rate of GTP hydrolysis via both intrinsic and GTPase-activating protein-catalyzed mechanisms, resulting in the perpetual activation of Ras pathways. We describe a fragment screening campaign using X-ray crystallography that led to the discovery of three fragment binding sites on the Ras:SOS complex. The identification of tool compounds binding at each of these sites allowed exploration of two new approaches to Ras pathway inhibition by stabilizing or covalently modifying the Ras:SOS complex to prevent the reloading of Ras with GTP. Initially, we identified ligands that bound reversibly to the Ras:SOS complex in two distinct sites, but these compounds were not sufficiently potent inhibitors to validate our stabilization hypothesis. We conclude by demonstrating that covalent modification of Cys118 on Ras leads to a novel mechanism of inhibition of the SOS-mediated interaction between Ras and Raf and is effective at inhibiting the exchange of labeled GDP in both mutant (G12C and G12V) and wild type Ras.

Citing Articles

Oncogenic mutant KRAS inhibition through oxidation at cysteine 118.

Kramer-Drauberg M, Petrini E, Mira A, Patrucco E, Scardaci R, Savinelli I Mol Oncol. 2025; 19(2):311-328.

PMID: 39838816 PMC: 11793020. DOI: 10.1002/1878-0261.13798.


Monophthalates of betulinic acid and related pentacyclic triterpenes inhibit efficiently the SOS-mediated nucleotide exchange and impact PI3K/AKT signaling in oncogenic K-RAS4B proteins.

Benary G, Kilgenstein F, Koller S, Scherkenbeck J RSC Adv. 2025; 15(2):883-895.

PMID: 39802464 PMC: 11719397. DOI: 10.1039/d4ra08503e.


Exploration of Cryptic Pockets Using Enhanced Sampling Along Normal Modes: A Case Study of KRAS .

Vithani N, Zhang S, Thompson J, Patel L, Demidov A, Xia J J Chem Inf Model. 2024; 64(21):8258-8273.

PMID: 39419500 PMC: 11558672. DOI: 10.1021/acs.jcim.4c01435.


Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer.

Ghadrdoost Nakhchi B, Kosuru R, Chrzanowska M Int J Mol Sci. 2024; 25(18).

PMID: 39337337 PMC: 11432579. DOI: 10.3390/ijms25189853.


An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review.

Sabt A, Tawfik H, Khaleel E, Mustafa Badi R, Abdelsattar Ibrahim H, Elkaeed E Mol Divers. 2024; 28(6):4581-4608.

PMID: 38289431 DOI: 10.1007/s11030-023-10777-6.